With significant industry experience in fields such as molecular biology, bioinformatics, technology development and research leadership, the company’s senior management team uniquely positions DNA2.0 as an industry-leading enabler of visionary products and services. DNA2.0’s visionary biotech leadership has improved the way people research, create and live, one gene at a time.
Jeremy Minshull, Ph.D.
Chief Executive OfficerDr. Jeremy Minshull has served as President/CEO of DNA2.0 since co-founding the company in 2003. Previously, he was Vice President of Core Technology at Maxygen Inc., where he developed new technologies and scientific infrastructure to support directed evolution projects in chemical, agricultural and human therapeutic areas. He also held an early position at Affymax, where he helped develop and enable DNA shuffling. Dr. Minshull has received several industry awards, holds 54 patents, is a member of several professional societies, and has authored or co-authored >40 peer-reviewed papers. Dr. Minshull was a post-doctoral fellow at UC San Francisco, and received his Ph.D. from the University of Cambridge, where he studied basic control of the eukaryotic cell cycle with Nobel laureate Dr. Tim Hunt. Minshull received an honors degree in Natural Sciences (Biochemistry) from Sidney Sussex College, University of Cambridge, England.
Claes Gustafsson, Ph.D.
Chief Commercial OfficerAs DNA2.0’s Co-Founder and CCO, Dr. Gustafsson oversees most of the company’s external communications. Prior to co-founding DNA2.0, Gustafsson was Scientist and later Manager at Maxygen Inc., where he led, managed and collaborated with key strategic teams for more than five years. He also held a Scientist position at Kosan Biosciences, as well as a number of research, teaching, and post-doctoral positions at UCs Santa Cruz and San Francisco, and at University of Umeå. He holds 43 issued U.S. patents and has published >40 scientific papers. Gustafsson received his Ph.D. in Molecular Biology/Biochemistry from the University of Umeå, Sweden (Heja Löven) where he studied translation under Prof Glenn Björk.
Jon Ness, Ph.D.
Chief Scientific OfficerDr. Jon Ness is a co-founder of DNA2.0 and has coordinated the DNA2.0 technology development since its inception. Prior to his tenure at DNA2.0, Ness was one of the first employees at Maxygen Inc., where he led Maxygen’s DNA Shuffling Technology Development Group. He also served as project leader for Maxygen’s collaborative partnership with Novozymes, focusing on improving industrial enzymes, including the laundry detergent protease subtilisin. As a post-doctoral fellow at Affymax, Ness laid the groundwork for in vivo recombination and whole genome shuffling in microorganisms. Dr. Ness holds 18 patents and is the co-author of 10 peer-reviewed articles. He received a Ph.D. in Bacterial Genetics and Physiology from UC Davis, and a BS in Microbiology from the University of Minnesota.
Sridhar Govindarajan, Ph.D.
Chief Information OfficerAs DNA2.0’s Co-founder and CIO, Dr. Sridhar Govindarajan leads the company’s automation and protein engineering efforts. He offers more than 20 years of scientific computing experience. Prior to his current position, Govindarajan led the computational research in optimizing directed evolution technologies at Maxygen, Inc., and was a Systems Architect at EraGen Biosciences. Govindarajan conducted graduate-level research at the University of Michigan’s Department of Chemistry, and was a Junior Research Fellow at the Indian Institute of Technology (IIT)’s Department of Chemistry. In addition to his role at DNA2.0, Govindarajan contributes to the science community through industry event presentations and the publishing of more than 40 papers, including a 2008 peer-reviewed paper in Nature. He received his Ph.D. in Computational Chemistry/Biophysics from the University of Michigan and holds an undergraduate degree in Chemistry from IIT in Mumbai, India.
Howard Simon, J.D., M.B.A.
Chief Operating Officer & General CounselHoward Simon is Chief Operating Officer & General Counsel at DNA2.0, where his responsibilities include general operations, legal matters (including compliance and biosecurity), and human resources. Mr. Simon joined DNA2.0 in March 2012 from InterMune, Inc., a global biotechnology company, where he was Senior Vice President, Human Resources & Corporate Services, Associate General Counsel, and Chief Compliance Officer. He also served as Senior Vice President, Human Resources and Associate counsel at Maxygen, Inc. Prior to his in-house roles, Mr. Simon was a partner in major San Francisco law firms representing clients in the life sciences and other industries. He holds a law degree from the Boalt Hall School of Law (UC Berkeley), an MBA from Babson College, a Master’s Degree from the Graduate Theological Union of Berkeley, and an undergraduate degree from UC Berkeley. Mr. Simon also is a certified Senior Human Resources Professional and Corporate Compliance and Ethics Professional.
Walter Tian, M.S., M.B.A.
SVP, Marketing & Corporate StrategyWalter Tian joined DNA2.0 in September 2011. As Senior Vice President for Marketing and Corporate Strategy, he leads DNA2.0’s sales and marketing activities in delivering high-quality and high-content gene synthesis services. Mr. Tian has more than seven years’ experience in biotechnology research and over 18 years in marketing and business management in the life sciences. Most recently, Mr. Tian was Vice President for Marketing at OriGene Technologies, Inc., where he led the marketing and product development efforts in transitioning the company’s business from cDNA products to complete gene-centric research solutions. Prior to OriGene, Mr. Tian spent five years as Global Business Director at QIAGEN, leading a global business unit focused on siRNA and miRNA portfolio development. Mr. Tian also has held management positions at PerkinElmer, Endogen, and T Cell Sciences. Mr. Tian received his MBA degree from Northeastern University, MS degree from Beijing Medical University, and a medical degree from Xi’An Medical College.
DNA2.0 is the leading bioengineering solutions provider. Founded in 2003, DNA2.0 offers an integrated pipeline of solutions for the research community, including gene design, optimization, synthesis and cloning, as well as platforms for protein and strain engineering. It is the fastest provider of synthetic genes—based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 is by far the most published synthetic gene vendor, providing expert support to and collaboration with scientists. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene design and synthesis processes and new protein optimization technologies. DNA2.0’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. The company is privately held and is headquartered in Menlo Park, California With a reverence for the interplay between science, technology and nature, DNA2.0 applies its proprietary ProteinGPS™ algorithm, which condenses genomic information into mathematical rules on how proteins function. Application of these rules allows for production of physical entities embodying specific features, using the company’s efficient DNA-2-Go™ gene synthesis process. The result: precise and robust algorithms that allow for engineering of any measurable property in any protein so that it fulfills the exact functional criteria needed for commercialization while consuming minimal resources. While leading the industry in creating value-added applications through gene synthesis and protein engineering, DNA2.0 has also chosen to emphasize customer service as a critical measure of success. The freely available DNA2.0 software tool Gene Designer and the online Bioinformatic toolbox (picked as Best of the Web by Genetic Engineering News) put all the tools and expertise needed for gene design at the fingertips of the user. The company positions itself as a resource and research partner for its customers, to enable accurate and innovative delivery of specific, immediately useful solutions. Customers value the individual, Ph.D.-level support they receive from DNA2.0’s sales and support staff, as well as the speed, accuracy, and flexibility with which products and services are delivered.
- 8,635,029 Systems and methods for biopolymer engineering. Gustafsson, Govindarajan and Minshull
- 8,412,461 Systems and methods for antibody engineering. Gustafsson, Govindarajan and Minshull.
- 8,401,798 Systems and methods for constructing frequency lookup tables for expression systems. Welch and Gustafsson.
- 8,158,391 Production of an α-carboxyl-ω-hydroxy fatty acid using a genetically modified Candida strain. Gross, Lu, Ness and Minshull.
- 8,126,653 Synthetic nucleic acids for expression of encoded proteins. Welch and Gustafsson.
- 8,005,620 Systems and methods for biopolymer engineering. Gustafsson, Govindarajan and Minshull.
- 7,805,252 Systems and methods for designing and ordering polynucleotides. Gustafsson, Govindarajan, Ness, Villalobos and Minshull.
- 7,561,973 Methods for determining properties that affect an expression property value of polynucleotides in an expression system. Welch and Gustafsson.
- 7,561,972 Synthetic nucleic acids for expression of encoded proteins. Welch and Gustafsson.
View all published articles from researchers at DNA2.0
Search the DNA2.0 Literature Database, containing over 800 scientific publications using DNA2.0 technology for references relevant to your research.
Proc Natl Acad Sci Northpole 2013 12:25-31. KRISPR-KRINGLEi Utilized for
Leptin Supression in Elves (Denisova hominin). Kane, Claes, Ness, Elf, Sridhar, and Menorah
Prof Laura Menorah’s team at the Univ Northpole utilizes the CRISPR system to improve Elf health.
Proc Natl Acad Sci Northpole 2012 12:25-31. Deconvolution of Inherent Genomic-Melodic Linkages, or The Music of Life. Claes, Navidad, Ness, Elf, Sridhar, Tinsel and Menorah
Prof Laura Menorah’s team at the Univ Northpole explores the relationship between ancestral genomic information and musical annotation.
Proc Natl Acad Sci Northpole 2011 12:25-31. Nine improved monomeric fluorescent proteins from Rangifer tarandus. Claes, Navidad, Ness, Elf, Sridhar, Tinsel and Menorah
Prof Laura Menorah's team at the Univ Northpole has used whole genome sequencing and genome-wide functional association studies to identify the red fluorescent protein, Rudolph. Directed evolution and protein engineering (ProteinGPS) further identified eight additional colors. The reindeer proteins are in the public domain and sold under the BioBrick Public Agreement.
Proc Natl Acad Sci Northpole 2010 12:25-31. Carolome: Functional Imprints of Culture Memes in Global Genome. Claes, Navidad, Ness, Baum, Elf, Sridhar, and Menorah
A research team lead by Prof Laura Menorah at the Univ Northpole has systematically identified Christmas carols deposited in sequence data, and established their direct role in the functional imprint and transfer of genetic information. They name this exciting new field of research Carolomics.
Nature 2009 458:703. For anyone who ever said there's no such thing as a poetic gene. Gustafsson
Correspondence to Nature regarding poetry in synthetic genomes.
Proc Natl Acad Sci Northpole 2008 12:25-31. Metabolic engineering of Picea abies for receptor mediated induction of fluorescence and olfactory signaling. Claes, Navidad, Ness, Baum, Harry, Sridhar, and Elf
In a concerted synthetic biology and tissue engineering effort, a team lead by Santa Claes at the Univ Northpole designed and constructed a christmas tree that induced endogenous fluorescent sparkling and olfactory emission after induction by christmas carols.
Proc Natl Acad Sci Northpole 2006 12:25. Heterologous expression and functional characterization of the Santa Hoho2 gene. Claes, Reindeer, Nicolas, Tomte, Sridhar, Elf
The Hoho2 gene responsible for facial hair formation of Santa Claus is isolated and shown to be an ortholog of human KRT6B. The Hoho2 gene was codon optimized and and the corresponding protein expressed in E. coli, reindeer and human. RNAi knockout constructs could be trans-complemented with an RNAi resistant Hoho2 variant. Brilliant science by Prof Elf and coworkers at Univ Northpole.
Int Pub 2005 12:25 Creation of the Tomten Gene G051225. Claes, Tomte, Sridhar, Elf
In an attempt to honor Tomten and investigate its molecular basis, DNA2.0 created the Tomten gene. The gene was codon optimized for expression in Reindeer, synthesized and cloned. Constructs successfully expressed the glowing snow of the Tomten.
Learn more about the Electra Vector System® and how it can benefit your research. DNA2.0 has developed a simple one-tube universal cloning process that can be performed in a 5 minute bench-top reaction with the fidelity of a restriction based cloning system. The system includes a collection of IP-Free bacterial, mammalian and yeast expression vectors that provide a quick and efficient way to test a gene of interest under control of various elements and are available with optional C- and N-terminal tags and/or fusions. Any vector can be easily “Electra-fied” (converted to function as an Electra vector), and DNA2.0 will assist anyone who wishes to do so.
View a pdf of the webinar slides.
Developed by DNA2.0, Gene Designer 2.0 is the ideal software to design sequences de novo without being limited by what nature can provide. It encompasses a complete and visually rich set of tools to bring your creative ideas to completion. We demonstrate how to design gene sequences as well as how to remove or add restriction sites or other motifs, primer design, cloning scheme, and many other features. March 8, 2012
Gene Designer software is available free of charge.
Learn how to review your sequences in Gene Designer prior to full sequence approval for production. Developed by DNA2.0, Gene Designer 2.0 is the ideal bioinformatics software to design sequences de novo without being limited by what nature can provide. November 7, 2012
Gene synthesis allows researchers to tailor gene sequences for optimal utility for any application. However, the relationship between gene sequence and expression is complex and depends on a wide range of sequence variables. DNA2.0 uses a systematic engineering approach, GeneGPS, to navigate these variables with a minimal number of test genes to optimize performance. Application of this approach with a variety of protein targets and expression hosts will be described. March 22, 2012
View a pdf of the webinar slides.
Protein variant libraries can allow exploration of "sequence space" over modest to very large areas. We discuss the basic library types, their strengths and possible uses. Use of single site saturation and combinatorial libraries to improve enzyme properties and Antibody libraries to increase antibody affinity are specific examples. Basic information required for DNA2.0 to provide useful Quotes for library synthesis is also discussed. April 5, 2012
View a pdf of the webinar slides.
ProteinGPS™ relies on identifying key amino acid substitutions through bioinformatics-based mining of available sequence space and combining such substitutions in information maximized Infologs – synthetic gene variants designed to be systematically varied across the searched space. The presentation includes recent case studies. April 19, 2012
View a pdf of the webinar slides.
Gene synthesis allows researchers to tailor gene sequences for optimal utility for any application. However, the relationship between gene sequence and expression is complex and depends on a wide range of sequence variables. DNA2.0 uses a systematic engineering approach, GeneGPS, to navigate these variables with a minimal number of test genes to optimize performance. Application of this approach with a variety of protein targets and expression hosts is described.
View a pdf of the DNA2.0 webinar slides.
Archive of a webinar by DNA2.0 and the AAAS, originally presented in October 2009. This webinar includes presentations by Joshua Plotkin, Ph.D., University of Pennsylvania; Christine Vogel, Ph.D., University of Texas at Austin; and Mark Welch, Ph.D., DNA2.0. October, 2009
- PepTalk, 2014: Leveraging Gene Synthesis for Systematic Optimization of Protein Production
- RAFT X 2013: Multidimensional Optimization of Biological Systems to Fit Industrial Applications
- SB6.0 Poster: IP-Free© Protein Paintbox™ – An Expansive Palette
- PEGS, 2013: Maximizing Recombinant Protein Expression through Systematic Gene Design
- PEGS, 2013 Poster: The Electra™ Vector System: Simple, IP-Free©, Scarless Cloning
- PepTalk, 2013: Infologs™ for Multi-dimensional Gene and Protein Optimization
- Society for Industrial Microbiology and Technology, 2012: Design of Functional Bio Constructs
- Next Generation Protein Therapeutics, 2012: Use of Infologs™ to Accelerate Bioengineering
- Autodesk Ideas Conference, 2012: Gene Synthesis + Machine Learning = BioDesign
- IBC Antibody Engineering and Therapeutics, 2011: Strategies for Maximizing Information Content in Protein Libraries
- Enzyme Engineering XXI, 2011: Using Infologs to Engineer Biological Systems